Navigation Links
Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
Date:5/3/2012

atients with lupus.  The primary endpoint of PEARL-SC requires patients to demonstrate a greater than or equal to five (>5) point reduction in the SELENA/SLEDAI clinical assessment score, no worsening in physician global assessment, and no new BILAG A or two or more new BILAG B organ domain scores.  Details regarding the study can be found at http://www.clinicaltrials.gov.
  • In conjunction with the PEARL-SC DSMB meeting, an independent statistician conducted an interim efficacy analysis after the 350th enrolled patient reached the 24-week time-point of the study. Following the results of the analysis, the statistician recommended the continuation of the PEARL-SC study to completion. The company is expecting final top-line data this quarter.
  • Manufacturing

  • The Company initiated the development of a pre-filled syringe for the self-administration of subcutaneously delivered blisibimod for phase 3 clinical studies. Stability testing is underway.
  • Management

  • Anthera announced the appointment of Dr. Bogdan Dziurzynski to the board of directors. Dr. Dziurzynski currently serves as a strategic regulatory management consultant to the biotechnology industry and serves on the Board of Directors of Dendreon Corporation and the Biologics Consulting Group, Inc.
  • *SELENA/SLEDAI -- Safety of Estrogen in Lupus Erythematosus National Assessment / Systemic Lupus Erythematosus Activity Index is a cumulative, weighted index of systemic lupus erythematosus disease activity.

    About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

    Safe Harbor Statement

    Any statements contained in this press release that refer to future events or other non-historical matters, including stateme
    '/>"/>

    SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/14/2014)... 2014 The legalization of medical and recreational ... as a new economic driver – that has taken ... the right response to the will of the people ... At a National Press Club Newsmakers news conference ... experts in the area of marijuana legalization will discuss ...
    (Date:7/14/2014)... 2014 Lumin Medical LLC, a healthcare IT ... the leading provider of on-demand patient tracking solutions and ... to Franklin, Wis. ... light and our mission is to provide visibility for ... and reduce costs," said James Hermann , President ...
    (Date:7/14/2014)... 14, 2014 Valeant Pharmaceuticals International, Inc. ... today announced it has filed a premerger notification ... (HSR) with the U.S. Federal Trade Commission (FTC) ... (NYSE: AGN). About Valeant Pharmaceuticals ... Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical ...
    Breaking Medicine Technology:NPC Newsmaker Program: Interpreting smoke signals from the marijuana skirmish line 2Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 2Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 3Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 4Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan 5
    ... Approximately ninety-one percent of dentists say patients complaining about dry ... survey conducted by the Academy of General Dentistry (AGD). ... decrease in salivary function. It affects approximately one in ... risk for tooth decay. During the Academy of General Dentistry,s ...
    ... Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that ... July 9, 2009 at 8:00 am EDT (5:00 am PDT). ... investigator of the trial will discuss results of the Company,s ... the Company,s plans for further development and related matters. ...
    Cached Medicine Technology:Dry Mouth Linked to Prescription and Over the Counter Drugs 2Dry Mouth Linked to Prescription and Over the Counter Drugs 3Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 2
    (Date:7/14/2014)... 2014 Acute coronary syndrome (ACS) ... healthcare costs, frequent recurrences and hospitalizations, and high ... ACS incidence increases with age and will be ... population increases around the world. ACS is classified ... heart muscle damage inferred from a person’s symptoms, ...
    (Date:7/14/2014)... 2014 Midway through summer, throngs of families ... the National Lampoon classic “Vacation.” An estimated four out of ... by Bridgestone Americas , embark on summer road trips. And ... nagging back pain as the result of hours cramped behind ... , “For these patients, riding in a car for an ...
    (Date:7/14/2014)... Institutes of Health (NIH) have identified genetic markers associated ... characterized by high levels of immune cells called eosinophils ... are involved in the development of EoE, which can ... allergies. The findings also may help explain why the ... in part by the Consortium of Food Allergy ...
    (Date:7/14/2014)... A recent study published in the July 2014 ... of Child and Adolescent Psychiatry confirms the validity ... criterion for diagnosis of attention-deficit/hyperactivity disorder (ADHD). , In ... at 7 in DSM-IV, has been raised to 12. ... set at 12, rather than an earlier age, to ...
    (Date:7/14/2014)... years that have passed since acupuncture was first ... used to treat a number of physical, mental ... rehabilitation, headaches, menstrual cramps, asthma, carpal tunnel, fibromyalgia ... Now, a meta-analysis of randomized controlled trials which ... , the journal of The North American Menopause ...
    Breaking Medicine News(10 mins):Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 2Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 3Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 4Health News:Top Orthopedic Surgeon Shares Seven Ways To Reduce Back Pain During Long Summer Road Trips 2Health News:Top Orthopedic Surgeon Shares Seven Ways To Reduce Back Pain During Long Summer Road Trips 3Health News:Scientists deepen genetic understanding of eosinophilic esophagitis 2Health News:Bothered by hot flashes? Acupuncture might be the answer 2
    ... and his colleagues from the Stanford University School of Medicine ... Cancer Research. The result of the study has found that ... to reduce the growth of cancer in patients with prostate ... two drugs reduces the growth of prostate cancer by 70 ...
    ... researchers from University of South Florida had reported in ... Sciences that the more nature of mental exercise performed ... reducing the risk of dementia in later life.// ... lifetime occupation and risk for Alzheimer’s disease and dementia ...
    ... Kolkata (6th Sept 2005): In an alarming announcement the ... that West Bengal was facing a Dengue epidemic and the ... last year.// ,Mishra also said that other than ... the people, especially in Kolkata. ,Dengue was also ...
    ... low dose of Vitamin D with non-steroidal anti- inflammatory ... says a study.// ,David Feldman and other researchers ... a form of Vitamin D, combined with an over-the-counter ... online edition of Ivanhoe Broadcast News. ,The researchers ...
    ... of had discovered a new way to test the ... attack. // ,The researchers had used a ... cells’ destinations after being injected into the body to ... attack. ,In the study, researchers surgically ...
    ... from anorexia nervosa have the similar brain activities that ... study was published in the September issue of Archives ... alterations in the activity of serotonin (a brain chemical ... the appetite alteration in anorexia nervosa as well as ...
    Cached Medicine News:
    ... Selecta Duo Adding the ... platform creates the Selecta Duo, ... nm Photocoagulator combination laser that ... involving both the anterior segment ...
    Patient-Centered Therapy that promotes natural cardiac function....
    ... The Apeel CS Catheter Delivery System ... used for the placement of permanent ... Apeel CS Catheter Delivery System is ... torqueability, flexibility, and softness, plus high ...
    ... Alliance Catheter Delivery System (CDS) ... stabilization of the Aescula LV ... has a patented coronary sinus ... and easy access to the ...
    Medicine Products: